On November 21, 2024 Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, reported that the Company will deliver a poster presentation highlighting preclinical data that support SKY-1214 as a potential treatment for relapsed/refractory (R/R) multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) at the upcoming 66th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting taking place December 7-10, 2024 in San Diego, California (Press release, Skyhawk Therapeutics, NOV 21, 2024, View Source [SID1234648552]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details for the poster presentation are as follows:
Title: "SKY-1214, a Small Molecule Splicing Modulator
Targeting FANCL and FANCI, Provides a New
Mechanism of Action Targeting Multiple
Myeloma and Non-Hodgkin’s Lymphoma"
Presenter: Steven Taylor, PhD, Head of Business Development and Operations
Session Name: 605. Molecular Pharmacology and Drug Resistance:
Lymphoid Neoplasms: Poster II
Poster Number: 2784
Date/Time: Sunday, December 8, 2024 from 6:00 PM – 8:00 PM PST
Location: San Diego Convention Center, Halls G-H
"Having already shown strong monotherapy potential, we are pleased to be sharing these encouraging preclinical data that demonstrate SKY-1214’s anti-cancer activity in combination with key existing and emerging treatment options," said Clint Musil, CEO at Skyhawk. "The increasing number of patients with relapsed/refractory multiple myeloma and Large B-cell Lymphoma after chemotherapy and immunotherapies necessitates new, effective and convenient therapies that will increasingly be used in combination. The understanding of RNA biology and the capacity to develop oral drugs for "undruggable" protein targets opens a new opportunity to address these treatment needs."
About SKY-1214
SKY-1214 is a first-in-class, oral FANCL/FANCI targeting RNA splicing modulator being developed for difficult to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). FANCL/FANCI are critical components of the Fanconi anemia DNA damage repair pathway, which MM and NHL tumor cells use to maintain their genome integrity. Skyhawk has observed anti-tumor activity for SKY-1214 in several preclinical cell models, including those representing prevalent high-risk cytogenetic alterations. SKY-1214 also demonstrated anti-tumor activity in human tumor cell-derived xenograft mouse models correlating with FANCL/FANCI mRNA reduction. Combinations of SKY-1214 with commonly used and emerging treatments for MM and NHL resulted in additive and synergistic effects, demonstrated tumor regressions, and showed enhanced durability of effect upon treatment cessation. SKY-1214 has completed IND-enabling studies.